Menu
Not yet recruiting NCT07329556

Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases

— Observational Rheumatoid Arthritis (RA Ankylosing Spondylitis Psoriatic Arthritis Reactive Arthritis (ReA)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Rheumatoid Arthritis (RA, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis (ReA). Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Evaluation of Advanced Glycation End Products Accumulation in Rheumatic Diseases Using Non-Invasive Skin Autofluorescence Measurements

Overview

Rheumatic diseases are chronic inflammatory conditions that can lead to long-term tissue damage and increased cardiovascular and metabolic risk. Advanced glycation end products (AGEs) are harmful molecules that accumulate in the body over time and are known to promote inflammation and oxidative stress. Increased AGE burden has been implicated in several chronic diseases; however, its role in rheumatic diseases has not been fully clarified. This observational, cross-sectional study aims to evaluate the accumulation of AGEs in patients with various rheumatic diseases compared with healthy individuals. AGE levels will be assessed non-invasively using skin autofluorescence measurements. By comparing AGE burden between patients and healthy controls, this study seeks to improve understanding of the potential role of AGEs in the pathophysiology of rheumatic diseases and to explore their usefulness as a non-invasive biomarker in clinical practice.

Primary outcome measures

  • Skin Autofluorescence-Derived Advanced Glycation End Product Level [Time frame: Baseline (single study visit)]
Secondary outcome measures (2)
  • Comparison of AGE Levels Between Rheumatic Disease Subtypes [Time frame: Baseline (single study visit)]
  • Association Between AGE Levels and Inflammatory Markers [Time frame: Baseline]

Eligibility criteria

Inclusion criteria

  • Age between 18 and 75 years
  • Diagnosis of an inflammatory rheumatic disease (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, connective tissue diseases, Behçet disease, familial Mediterranean fever, or crystal arthropathies), confirmed by a rheumatologist
  • Healthy volunteers without a history of rheumatic or chronic inflammatory disease (for the control group)
  • Ability to undergo non-invasive skin autofluorescence measurement
  • Ability and willingness to provide written informed consent

Exclusion criteria

  • Diagnosis of diabetes mellitus (type 1 or type 2)
  • Chronic kidney disease with estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m²
  • Active malignancy or history of malignancy within the past 5 years
  • Presence of acute infection or acute inflammatory condition at the time of assessment
  • Secondary causes of systemic inflammation unrelated to the underlying rheumatic disease (e.g., uncontrolled endocrine disorders, chronic liver disease)
  • Use of medications known to markedly affect AGE accumulation or skin autofluorescence measurements (e.g., recent high-dose systemic glucocorticoids)
  • Pregnancy or breastfeeding
  • Presence of significant skin conditions (e.g., extensive dermatitis, scars, tattoos, or burns) at the measurement site that may interfere with skin autofluorescence assessment
  • Inability to comply with study procedures or to provide informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Case-control

Study locations

Center list to be confirmed — check the primary protocol.

Publications

  • de Groot L, Hinkema H, Westra J, Smit AJ, Kallenberg CG, Bijl M, Posthumus MD. Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease. Arthritis Res Ther. 2011;13(6):R205. doi: 10.1186/ar3538. Epub 2011 Dec 14. PMID 22168993

Identifiers

NCT: NCT07329556 · 2026-Rheumatology-1

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗